Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuluo Penyánqing capsule is a traditional Chinese medicine (TCM) candidate developed by Guangzhou Lanyun Pharmaceutical Research Co., Ltd. for the treatment of sequelae of pelvic inflammatory disease (SPID). It is specifically formulated to target the TCM syndrome of damp-heat with blood stasis, a common pathological pattern in chronic pelvic inflammation. The therapeutic approach focuses on clearing heat, resolving dampness, and promoting blood circulation to alleviate pelvic pain and improve local signs of inflammation. The drug has been evaluated in Phase 2 clinical trials in China to determine its optimal dosage, safety, and efficacy compared to placebo over a 12-week treatment period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tuluo Penyánqing capsule.